About Cardia
Cardia is a Healthcare company based in Eagan (United States) founded in 1998. Products for transvenous closures of certain types of congenital heart defects. Its focus areas include Life Sciences, Cardiac and Vascular Disorders, Medical Devices and Therapeutic Devices. Its legal entity is CARDIA, INC. Its competitors include PECA Labs, Endonovo Therapeutics and AdvancedCPR Solutions; 2 of its 3 listed competitors have raised funding.
Company details
Cardia is engaged in developing, manufacturing and marketing transcatheter septal occluders for the transvenous closures of certain types of congenital heart defects. Products include Ultrasept ASD, for the transvenous closure of atrial septal defects; Ultrasept PFO, for the percutaneous closure of patent foramen ovale, including those with aneurysm; Ultrasept LAA, for the transvenous closure of the left atrial appendage; Ultrasept Cribriform Device, for the transvenous closure of a multifenestrated septum; Fontan Occluder, for the transvenous closure of a fenestrated fontan and Cardia Delivery System, includes braided delivery sheath, dilator, and introducer with side flushing port. Claims to have closed over 15,000 septal defects worldwide.
- Headquarters Eagan, United States
- SectorsHealthcare
- Website cardia.com
- Social LinkedIn X
- Legal Name Cardia, Inc.
- Latest Funding Round$364.44K (USD), Unspecified
Nov 2019
Funding Insights of Cardia
- Total Rounds 7
- Last Round Unspecified — $364,443
- First Round $2.08M
(Jul 2011)
All 7 funding rounds of Cardia with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2019 | $364,443 | Unspecified | – | – | – |
| Jun 2016 | $750,000 | Unspecified | – | – | – |
| Jun 2015 | $250,005 | Unspecified | – | – | – |
| Jun 2013 | $550,005 | Unspecified | – | – | – |
| May 2013 | $400,005 | Unspecified | – | – | – |
| Oct 2012 | $1.25M | Unspecified | – | – | – |
| Jul 2011 | $2.08M | Unspecified | – | – | – |
Timeline of Cardia
3 dated milestones of Cardia across 21 years, from founding to its latest funding, stage changes and deals.
- Founded Cardia is founded.
- Funding First funding round of $2.1M.
- Funding Latest funding round, Unspecified, of $364K.
Competitors of Cardia
Cardia has 3 listed competitors in our database, 2 of them funded. They include PECA Labs, Endonovo Therapeutics and AdvancedCPR Solutions.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pecalabs.com | 2011 | Pittsburgh, United States | $19.91M | Pediatric cardiac surgical devices are developed for congenital heart defects. | ||
| endonovo.com | 2011 | Los Angeles, United States | Bioelectronic devices are developed for regenerative medicine therapies. | |||
| elevatedcpr.com | 2015 | Edina, United States | $9.51M | CPR products for sudden cardiac arrest treatment are developed. |
Detailed competitors of Cardia
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Cardiac and Vascular Disorders
3 companies that operate in the same segment as Cardia (Cardiac and Vascular Disorders) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Gene-editing therapies for coronary artery disease are developed. | 2018 | Cambridge, Massachusetts, United States | USD 215.5 M | 255 | ||
Cardiac monitoring devices and applications are provided for heart health. | 2010 | Mountain View, California, United States | USD 114.38 M | USD 6.18 M | 67 | |
Therapies for lowering low-density lipoprotein cholesterol levels are developed. | 1998 | Ann Arbor, Michigan, United States | USD 129.7 M | USD 332.31 M | 304 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Cardia
Cardia was founded in 1998 and raised its 1st funding round 13 years after it was founded.
Cardia is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Cardia is engaged in developing, manufacturing and marketing transcatheter septal occluders for the transvenous closures of certain types of congenital heart defects. Products include Ultrasept ASD, for the transvenous closure of atrial septal defects; Ultrasept PFO, for the percutaneous closure of patent foramen ovale, including those with aneurysm; Ultrasept LAA, for the transvenous closure of the left atrial appendage; Ultrasept Cribriform Device, for the transvenous closure of a multifenestrated septum; Fontan Occluder, for the transvenous closure of a fenestrated fontan and Cardia Delivery System, includes braided delivery sheath, dilator, and introducer with side flushing port. Claims to have closed over 15,000 septal defects worldwide.
Cardia's top competitors include PECA Labs, Endonovo Therapeutics and AdvancedCPR Solutions.
Cardia operates through Cardia, Inc..